Basilea Pharmaceutica (FRA:PK5) FFO


FRA:PK5 Basilea Pharmaceutica Ltd FRA:PK5
62 GF Score
Price €56.30
GF Value €62.24
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica FFO?

FFO (Funds from operations) only applies to REITs.

FRA:PK5
62GF Score
Basilea Pharmaceutica Ltd FRA:PK5
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Basilea Pharmaceutica (FRA:PK5) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of €56.30 is trading 9.5% below its estimated GF Value™ of €62.24. GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.

Key valuation signals for FRA:PK5:

  • FFO:
  • GF Value™: €62.24 vs. price of €56.30 (9.5% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the FRA:PK5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score

Get the complete analysis for FRA:PK5

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.30
Price
€62.24
GF Value